<br /> ​Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.
Maria-Victoria Mateos, MD, PhD, director of the Myeloma Unit at University Hospital of Salamanca-IBSAL Salamanca, Spain, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.
At a median follow-up of 28 months, data confirmed that the addition of daratumumab (Darzalex) to bortezomib, melphalan, and prednisone (VMP) is significantly superior to VMP alone, says Mateos. This is confirmed in terms of overall response rate, complete response rate, and progression-free survival (PFS).
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More